drugset / Trial / NCT00651703

Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients

NCT00651703

Phase 2 Completed 21 enrolled Cytos Biotechnology AG
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate a specific cellular immune response in melanoma patients that have been vaccinated with a Melan-A VLP vaccine alone or in combination with different adjuvants.

Timeline

Start
2008-04
Primary completion
2009-12
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject CYT004-MelQbG10 Vaccine Other
Subject Imiquimod Other / unclassified
Subject Montanide Other / unclassified

Indications